Navigation Links
Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/14/2013

ax rates).  Non-GAAP net income excludes the release of the valuation allowance described above, as well as non-cash income tax expense.  The Company does not currently pay, or expect to pay in the near future, significant cash income taxes.  When the Company begins paying significant cash income taxes, it expects to no longer exclude non-cash income tax expense from non-GAAP net income.

Non-GAAP and GAAP Net Income (Loss): The Company reported non-GAAP net income of $171 million, or $1.79 per basic share and $1.47 per diluted share, in the fourth quarter of 2012, compared to a non-GAAP net loss of $34 million, or $0.37 per share (basic and diluted), in the fourth quarter of 2011.  The Company reported non-GAAP net income of $530 million, or $5.60 per basic share and $4.66 per diluted share, for the full year 2012, compared to a non-GAAP net loss of $162 million, or $1.79 per share (basic and diluted), for the full year 2011.  Non-GAAP net income (loss) excludes non-cash share-based compensation expense, non-cash interest expense related to the convertible senior notes, and non-cash income tax expense or benefit. 

The Company reported GAAP net income of $470 million, or $4.92 per basic share and $4.08 per diluted share, in the fourth quarter of 2012, compared to a GAAP net loss of $53 million, or $0.58 per share (basic and diluted), in the fourth quarter of 2011.  The Company reported GAAP net income of $750 million, or $7.92 per basic share and $6.75 per diluted share, for the full year 2012, compared to a GAAP net loss of $222 million, or $2.45 per share (basic and diluted), for the full year 2011.

Cash Position: At December 31, 2012, cash and marketable securities totaled $588 million (including $8 million of restricted cash and marketable securities), compared to $811 million (including $8 million of restricted cash and marketable securities) at December 31, 2011.  In addition, accounts receivable re
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
2. Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
3. Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
4. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
5. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
6. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
7. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
8. Regeneron Announces September 2012 Investor Conference Presentations
9. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
10. Regeneron Announces June 2012 Investor Conference Presentations
11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  Mytrus, a technology and services company revolutionizing ... electronic informed consent has received approval for use by ... It is the first time e-Consent technology will be ... . Mytrus was also the first ... clinical trial by the U.S. Food and Drug Administration ...
(Date:8/27/2015)... 27, 2015   Americord Registry , a private ... placenta tissue banking company, announced today the ... website. This new website makes the expecting parent,s cord ... shopping cart and checkout process. Logo - ... banking websites make this service difficult to purchase online. ...
(Date:8/27/2015)... 2015 According to a ... titled "Global Market Study on Urinary Catheters: Intermittent ... the urinary catheters market is expected to be valued at ... is anticipated to expand at a CAGR of4.1% ... by 2021. View full report TOC at: ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... BEDFORD, Ohio,  April 18, 2011 Bedford Laboratories™, ... pleased to announce the addition of Topotecan Hydrochloride ... portfolio.  Topotecan is AP Bioequivalent to the reference ... injection by GlaxoSmithKline. Topotecan Hydrochloride for Injection is ...
... April 18, 2011 Qmed.com, a UBM Canon ... informative video clips of products and services available ... Vault . Qmed is a free online search ... access to pre-qualified medical device suppliers. ...
Cached Medicine Technology:Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial 2Qmed Video Vault Showcases Innovative New Products and Services Available to Medical Device Manufacturers 2
(Date:8/28/2015)... Rochester, NY (PRWEB) , ... August 28, 2015 , ... ... injectable, Kybella™. It is the first and only nonsurgical product approved by the ... Dr. Vito Quatela and Dr. William Koenig are among ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout Southern ... sea diving. The act of recreational diving exposes the body to extreme ... is vital that all recreational and professional divers undergo regular comprehensive scuba physicals. ...
(Date:8/28/2015)... IN (PRWEB) , ... August 28, 2015 , ... ... benefits advisory organization, is pleased to welcome TJS Insurance Group as its newest ... employees and clients guides them and keeps them focused on their goals. Within ...
(Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... swift actions to be taken in order to ease the stress on the ... scientists have yet to understand fully the real cause of global warming and urges ...
(Date:8/28/2015)... MA (PRWEB) , ... August 28, 2015 , ... ... International, Inc. ’s online medical consultations result in high percentages of change to ... by the Center for Healthcare Informatics at Tennessee Tech University and analyzed WorldCare’s ...
Breaking Medicine News(10 mins):Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... may be possible with many low energy treatments than ... ,The results of this study were published in ... eight participants over a three-month period during which they ... regeneration treatments are done to reduce wrinkles and for ...
... of 654 new cases of dengue fever were reported across ... average of 400 new //cases a day last week, Paraguay's ... Nicanor Duarte Frutos has not yet declared the epidemic to ... declaration. ,Dengue fever is a viral infection ...
... with a condition that is a strong genetic predictor ... genetic counseling or cancer screening. //According to a recent ... screening rates could be improved if physicians provided stronger ... screening to their patients. ,“We studied families with ...
... New Delhi: The eradication of neglected tropical diseases should ... the World Health Organization (WHO).// ,Many people ... leprosy, lymphatic filaria, leishmaniasis and yaws. Dengue is emerging ... ,"These diseases cause great suffering and ill-health and have ...
... - A new study by researchers from Queen's University ... eye movement tests in the diagnosis of fetal alcohol ... called FASD affects children when mothers have consumed alcohol ... tasks, could help effectively measure FASD in children, the ...
... approved meat and milk from cloned animals while it conducts ... its customers and consumers don't want milk from cloned animals. ... among dozens of other brands. ,"Numerous surveys ... products that contain milk from cloned cows and Dean Foods ...
Cached Medicine News:Health News:WHO Urges Higher Priority for Neglected Diseases 2Health News:Milk from Cloned Cows is Not Welcome at the Nation's Biggest Milk Company 2
The Simpulse®VariCare™ System provides an innovative system for enhanced wound management which emphasizes performance, simplicity, safety, value, and support....
... Staple is a novel shape memory alloy bone ... of its Nitinol construction, the prongs of the ... upon application of a heating current. This results ... response of bone and cause adjustable compression across ...
... The Biomet ... is ideally suited ... This second-generation nail ... sharing fixation that ...
... SOF'WIRE Cable System provides immediate, stable, ... to conventional monofilament wire, SOF'WIRE is ... with ease and reproducibility. Stainless Steel ... optimal strength, durability and conformity. ...
Medicine Products: